<DOC>
<DOCNO>EP-0615755</DOCNO> 
<TEXT>
<INVENTION-TITLE>
Use of tetrahydropyridine derivatives for the manufacture of cardioprotective medicaments
</INVENTION-TITLE>
<CLASSIFICATIONS>A61K3144	A61K31445	A61P910	A61P908	C07D21170	A61K3144	A61K31445	A61P900	C07D21100	A61P900	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>A61K	A61K	A61P	A61P	C07D	A61K	A61K	A61P	C07D	A61P	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>A61K31	A61K31	A61P9	A61P9	C07D211	A61K31	A61K31	A61P9	C07D211	A61P9	</CLASSIFICATIONS-FOURTH>
<ABSTRACT>
The present invention relates to the use of a 1-[2-naphthylethyl]-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydro-pyr idine of formula (I) 
<
IMAGE
>
 or of its addition salts with pharmaceutically acceptable acids for the preparation of cardioprotective medicaments.
</ABSTRACT>
<APPLICANTS>
<APPLICANT-NAME>
SANOFI SYNTHELABO
</APPLICANT-NAME>
<APPLICANT-NAME>
SANOFI-SYNTHELABO
</APPLICANT-NAME>
</APPLICANTS>
<INVENTORS>
<INVENTOR-NAME>
CHATELAIN PIERRE PAUL
</INVENTOR-NAME>
<INVENTOR-NAME>
MANNING ALLAN STEWART
</INVENTOR-NAME>
<INVENTOR-NAME>
CHATELAIN, PIERRE PAUL
</INVENTOR-NAME>
<INVENTOR-NAME>
MANNING, ALLAN STEWART
</INVENTOR-NAME>
</INVENTORS>
<CLAIMS>
Use of a compound of formula (I)


   or of a pharmaceutically acceptable salt thereof, for the preparation of
pharmaceutical compositions intended for the treatment of heart failure,

coronary vasospasm, angina pectoris, valvular heart prolapse, for the prevention

of a second heart attack, for the treatment and/or prophylaxis of heart
inflammatory pathologies, for the prevention or treatment of side-effects caused

by cardiotoxic medicaments, or for the treatment of patients subjected to heart
surgery.
Use according to claim 1 
characterized in that
 the compound of formula
(I) is 1-[2-(2-naphtyl)ethyl]
-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine
or a pharmaceutically acceptable salt thereof.
Use according to claim 2 
characterized in that
 the compound of formula
(I) is 1-[2-(2-naphtyl)ethyl]
-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine
hydrochloride.
Use according to one of claims 1 to 3, 
characterized in that
 the
pharmaceutical composition is intended for the prevention or treatment of side

effects caused by an anticancer medicament.
Use according to claim 4, 
characterized in that
 the anticancer
medicament belongs to the anthracycline family.
</CLAIMS>
</TEXT>
</DOC>
